[
  {
    "ts": null,
    "headline": "Moderna Refocuses On Rare Diseases As New Leadership Shapes Pipeline",
    "summary": "Moderna (NasdaqGS:MRNA) announced a collaboration with Recordati to develop and commercialize mRNA-3927 for propionic acidemia, a rare genetic metabolic disorder. The company is also reshaping its leadership team, appointing David Berman as Chief Development Officer and confirming the departure of Chief Medical Officer Jacqueline Miller. These announcements focus attention on Moderna's push into rare diseases alongside leadership changes that may influence its development priorities beyond...",
    "url": "https://finnhub.io/api/news?id=4e1381bb5de7ca665d07520ac0c53a3ad7bf02dff4485932577a6dbcca513073",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769947882,
      "headline": "Moderna Refocuses On Rare Diseases As New Leadership Shapes Pipeline",
      "id": 138323907,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna (NasdaqGS:MRNA) announced a collaboration with Recordati to develop and commercialize mRNA-3927 for propionic acidemia, a rare genetic metabolic disorder. The company is also reshaping its leadership team, appointing David Berman as Chief Development Officer and confirming the departure of Chief Medical Officer Jacqueline Miller. These announcements focus attention on Moderna's push into rare diseases alongside leadership changes that may influence its development priorities beyond...",
      "url": "https://finnhub.io/api/news?id=4e1381bb5de7ca665d07520ac0c53a3ad7bf02dff4485932577a6dbcca513073"
    }
  },
  {
    "ts": null,
    "headline": "Is Moderna (MRNA) Pricing Fair After Recent 42.8% Monthly Share Price Jump",
    "summary": "If you are wondering whether Moderna's share price still reflects its underlying worth, it helps to start with the recent share price performance and how it lines up with the current valuation checks. Moderna closed at US$44.07, with a 9.5% decline over the last 7 days, a 42.8% gain over the last 30 days, a 42.8% return year to date, an 11.8% return over the last year, and a 74.6% and 75.0% decline over the last 3 and 5 years respectively. Recent market attention on Moderna has centered on...",
    "url": "https://finnhub.io/api/news?id=0ee91b564c9347111f7211cb4b94fa6158a8310c5642b658e6c728689aa90e66",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769922459,
      "headline": "Is Moderna (MRNA) Pricing Fair After Recent 42.8% Monthly Share Price Jump",
      "id": 138321556,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "If you are wondering whether Moderna's share price still reflects its underlying worth, it helps to start with the recent share price performance and how it lines up with the current valuation checks. Moderna closed at US$44.07, with a 9.5% decline over the last 7 days, a 42.8% gain over the last 30 days, a 42.8% return year to date, an 11.8% return over the last year, and a 74.6% and 75.0% decline over the last 3 and 5 years respectively. Recent market attention on Moderna has centered on...",
      "url": "https://finnhub.io/api/news?id=0ee91b564c9347111f7211cb4b94fa6158a8310c5642b658e6c728689aa90e66"
    }
  }
]